Bio-Inks and methods of using compositions comprising the bio-Inks are disclosed. 3-D tissue repair and regeneration through precise and specific formation of biodegradable tissue scaffolds in a tissue site using the bio-inks are also provided. Specific methylacrylated gelatin hydrogels (MAC) and methacrylated chitosan (MACh) preparations formulated with sucrose, a silicate-containing component (such as laponite), and/or a cross-linking agent (such as a photo-initiator or chemical initiator), as well as powdered preparations of these, are also disclosed. Kits containing these preparations are provided for point-of-care tissue repair in vivo. Superior, more complete (up to 99.85% tissue regeneration within 4 weeks applied in situ), and rapid in situ tissue repair and bone formation are also demonstrated.

Bio-Inks and methods of using compositions comprising the bio-Inks are disclosed. 3-D tissue repair and regeneration through precise and specific formation of biodegradable tissue scaffolds in a tissue site using the bio-inks are also provided. Specific methylacrylated gelatin hydrogels (MAC) and methacrylated chitosan (MACh) preparations formulated with sucrose, a silicate-containing component (such as laponite), and/or a cross-linking agent (such as a photo-initiator or chemical initiator), as well as powdered preparations of these, are also disclosed. Kits containing these preparations are provided for point-of-care tissue repair in vivo. Superior, more complete (up to 99.85% tissue regeneration within 4 weeks applied in situ), and rapid in situ tissue repair and bone formation are also demonstrated.

The present invention provides a pharmaceutical composition comprising a mushroom, a rhizome, a fruit, a leaf, a flower, an alga, an energy-rich liquid, a salt-rich liquid, an assist agent and an anti-oxide agent. Said pharmaceutical composition has ability to protect liver, improve autoimmunity, reduce pain caused by cancer, protect an organ from the side-effects caused by chemical cancer drugs and increase the functions of chemical cancer drugs.

The present invention provides a pharmaceutical composition comprising a mushroom, a rhizome, a fruit, a leaf, a flower, an alga, an energy-rich liquid, a salt-rich liquid, an assist agent and an anti-oxide agent. Said pharmaceutical composition has ability to protect liver, improve autoimmunity, reduce pain caused by cancer, protect an organ from the side-effects caused by chemical cancer drugs and increase the functions of chemical cancer drugs.

The present disclosure provides a theaflavin composition capable of promoting wound healing as well as a preparation method and use thereof. The theaflavin composition comprises theaflavin 3′-digallate or crude theaflavins as the main component; when the theaflavin composition comprises the theaflavin-3-3′-digallate as the main component, it further comprises component A or component B, or further comprises both component A and component B; when the theaflavin composition comprises the crude theaflavins as the main component, it further comprises component B, in which component A comprises sodium acetate, chitosan, and gelatin, and component B comprises glycerin, propylene glycol, triethanolamine, and Carbomer 940. The theaflavin composition provided by the present disclosure can significantly promote wound healing of diabetic mice.

The present invention provides a composition based on cannabidiol (CBD) and chitosan for use in reducing blood cholesterol, blood LDL and blood triglycerides levels.

The present invention provides a composition based on cannabidiol (CBD) and chitosan for use in reducing blood cholesterol, blood LDL and blood triglycerides levels.

The invention provides compositions and methods for treatment of gastrointestinal bleeding, such as upper GI bleeding. In certain aspects, the invention provides topical formulations that stop bleeding in the GI tract by forming a gel when a polymer in the formulation exceeds a threshold level (optionally a pre-determined threshold level) for a property of the polymer of the formulation, which threshold level may be for example, a physical (e.g., temperature), chemical (e.g., pH), or temporal threshold level following contact with the affected tissue. In certain aspects, a combination of properties, such as a combination of physical (e.g., temperature), chemical (e.g., pH), or temporal threshold levels determines when the polymer in the formulation transitions from a liquid to a gel. Methods of using such compositions are also provided.

The invention provides compositions and methods for treatment of gastrointestinal bleeding, such as upper GI bleeding. In certain aspects, the invention provides topical formulations that stop bleeding in the GI tract by forming a gel when a polymer in the formulation exceeds a threshold level (optionally a pre-determined threshold level) for a property of the polymer of the formulation, which threshold level may be for example, a physical (e.g., temperature), chemical (e.g., pH), or temporal threshold level following contact with the affected tissue. In certain aspects, a combination of properties, such as a combination of physical (e.g., temperature), chemical (e.g., pH), or temporal threshold levels determines when the polymer in the formulation transitions from a liquid to a gel. Methods of using such compositions are also provided.

Provided herein are chitosan-containing formulations, methods of making such formulations, and methods of using such formulations. Chitosan contemplated for use herein is preferably of high quality and its source is preferably of crustacean origin. The formulations contemplated herein are aqueous, either liquid- or viscous-like, varying in concentration and type of chitosan and acid used, and may include other components. Their uses are diverse, for oral/dental administration or topical/surface application to subjects (e.g. humans or animals) in need thereof or even food commodities, aiming to maintain a good condition where it is applied or contributing to health enhancement, healing, disease prevention or treatment. The present invention also relates to concentrated solutions that may be used for the formulation of other products.